Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women
Immunogenicity and Safety of the Quadrivalent HPV Vaccine Gardasil in Female Systemic Lupus Erythematosus Patients Aged 9-26
研究概览
详细说明
Female patients with systemic lupus erythematosus (SLE) have been found have higher rates of persistent HPV infections and precancerous lesions compared to the healthy population. The HPV vaccine Gardasil has been found to be safe and efficacious in females aged 9 to 26 years. There are no data on the immunogenicity and safety of Gardasil in females with SLE. Immune dysfunction related to SLE itself and the immunosuppression secondary to treatment of SLE might prevent patients with SLE from developing an adequate immune response to the vaccine. Also, theoretically, the vaccine might induce a disease exacerbation or production of new autoantibodies.
The purpose of this study is to evaluate immunogenicity and safety of Gardasil and its effects on autoantibody profile in female SLE patients aged 9-26 years
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Illinois
-
Chicago、Illinois、美国、60637
- University of Chicago
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age: 9 to 26 years of age
- Gender: Female
- All patients must fulfill the revised American College of Rheumatology Classification Criteria for SLE diagnosis.
- Current SLEDAI score ≤ 6
- Written, witnessed informed consent and/or assent will be obtained from the subject and the subject's parents (if under 18 years of age) or legally acceptable representative prior to enrollment
Exclusion Criteria:
- Acute exacerbation of disease within past 30 days which required increase in corticosteroid dose, initiation of a new immunosuppressive medication, or hospitalization
- Current SLEDAI score > 6
- Patients who have received rituximab in the last 6 months, or are currently on cyclophosphamide treatment
- History of allergic disease or reactions likely to be exacerbated by any component of the study vaccine
- Previous administration of any HPV vaccine
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
其他:Gardasil
30 patients will receive 0.5 ml Gardasil vaccine at months 0,2, and 6.
|
0.5 ml Gardasil vaccine will be administered to each patient at months 0,2 and 6.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Anti-HPV 6 Seroconversion
大体时间:7 months
|
Percent Seropositive
|
7 months
|
Anti-HPV 6 GMT
大体时间:7 months
|
Geometric mean titre in milli-Merck units per ml (mMu/ml)
|
7 months
|
Anti-HPV 11 Seroconversion
大体时间:7 months
|
% Seropositive
|
7 months
|
Anti-HPV 11 GMT
大体时间:7 months
|
Geometric mean titre in milli-Merck units per ml (mMu/ml)
|
7 months
|
Anti-HPV 16 Seroconversion
大体时间:7 months
|
% Seropositive
|
7 months
|
Anti-HPV 16 GMT
大体时间:7 months
|
Geometric mean titre in milli-Merck units per ml (mMu/ml)
|
7 months
|
Anti-HPV 18 Seroconversion
大体时间:7 months
|
% Seropositive
|
7 months
|
Anti-HPV 18 GMT
大体时间:7 months
|
Geometric mean titre in milli-Merck units per ml (mMu/ml)
|
7 months
|
SLEDAI Change Score
大体时间:7 months
|
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): change from baseline to 7 months.
The SLEDAI scale is a weighted sum of 16 clinical and 8 laboratory items.
Scores range from 0 to 105 with higher scores indicating worse outcome.
The variable analyzed here is the 7 month score minus the baseline score.
Therefore negative values indicate an improvement in outcome.
|
7 months
|
次要结果测量
结果测量 |
大体时间 |
---|---|
Induction or Increase of Autoantibodies (Conversion From Negative Anti-RNP to Positive Anti-RNP) Anti-RNP
大体时间:7 months
|
7 months
|
Induction or Increase of Autoantibodies (Conversion From Negative Smith to Positive Smith)
大体时间:7 months
|
7 months
|
Induction or Increase of Autoantibodies (Conversion From Lupus Anticoagulant Negative to Lupus Anticoagulant Positive)
大体时间:7 months
|
7 months
|
合作者和调查者
调查人员
- 首席研究员:Linda Wagner-Weiner, MD、University of Chicago
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
Gardasil的临床试验
-
Laval UniversityCenters for Disease Control and Prevention完全的
-
London School of Hygiene and Tropical MedicineMerck Sharp & Dohme LLC; Public Health England; University of Cambridge主动,不招人
-
Murdoch Childrens Research InstituteLondon School of Hygiene and Tropical Medicine; National Institute of Hygiene and Epidemiology...完全的
-
University Hospital, Bordeaux未知
-
Merck Sharp & Dohme LLC完全的宫颈癌 | 外阴癌 | 阴道癌 | 人乳头瘤病毒感染 | 尖锐湿疣